建立妊娠期糖尿病治疗核心结局指标集的研究方案
本研究旨在为评估妊娠期糖尿病(PGDM)治疗干预效果的随机对照试验制定核心结局指标集(COS)。方案包括系统综述、三轮在线德尔菲调查和共识会议三个步骤,涉及患者、医护人员、研究者和政策制定者等多方利益相关者,最终COS将提高试验间可比性并减少研究浪费。
要点
- PGDM治疗研究结局选择异质性大,限制了研究间比较。
- COS制定采用系统综述、德尔菲调查和共识会议三步法。
- COS将优先纳入对所有利益相关者重要的结局,改善报告质量。
核心结论
- 制定COS可提高PGDM治疗随机对照试验结局报告的一致性和可比性。
研究设计与样本
- 研究方案包括三步:系统综述、三轮在线德尔菲调查和共识会议。
- 德尔菲调查采用9点Likert量表对结局重要性进行排序。
- 共识会议纳入各利益相关者组代表,最终确定COS。
关键数值与推荐
- 德尔菲调查中,利益相关者使用9点Likert量表对结局重要性进行评分。
- 完成德尔菲调查后符合纳入标准的结局将提交共识会议讨论。
临床怎么用
- COS将用于未来PGDM治疗随机对照试验的结局选择和报告。
- COS有助于减少研究浪费,优先收集和报告所有利益相关者关注的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pregestational diabetes mellitus (PGDM) is associated with adverse pregnancy outcomes including increased rates of caesarean section birth, macrosomia, congenital malformation, prematurity, admission to the neonatal intensive care unit and stillbirth. As a result, there has been an increase in interventions to improve outcomes in both mother and infant. To date, meaningful comparisons between these studies are limited due to heterogeneity in outcome selection and reporting. The aim of this study is to develop a core outcome set (COS) for randomised controlled trials evaluating the effectiveness of interventions for the treatment of pregnant women with PGDM. METHODS: The study consists of three steps. The first step is a systematic review of the literature to assess outcomes reported in randomised controlled trials assessing the effectiveness of interventions for the treatment of pregnant women with PGDM. The second step is a three round, online Delphi survey to prioritise these outcomes. In this step, stakeholders (including women with PGDM, healthcare workers, researchers and policymakers) will be asked to rank the importance of outcomes for inclusion in the COS using a 9-point Likert type scale. Outcomes that meet the inclusion criteria after completion of the Delphi surveys will be brought to the consensus meeting. The consensus meeting will be the third and final step, where the COS will be finalised. The consensus meeting will include members from each stakeholder group. DISCUSSION: This paper describes the process used to develop a COS for the reporting of studies evaluating the effectiveness of interventions in pregnant women with PGDM. The COS will enable greater comparison between and information synthesis across RCTs in the treatment of PGDM. In addition, this COS will also help improve trial reporting and minimise research waste by prioritising the collection and reporting of outcomes that matter to all relevant stakeholder groups. TRIAL REGISTRATION: This COS has been registered with the Core Outcome Measures in Effectiveness Trials (COMET) initiative ( http://www.comet-initiative.org/studies/details/1425 ) on the 4th of November 2019. The systematic review component of this study has also been registered with the International Prospective Register of Systematic Reviews (PROSPERO) ( https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020173549 ).
引用
- Kgosidialwa O, Bogdanet D, Egan A, et al. Developing a core outcome set for the treatment of pregnant women with pregestational diabetes-a study protocol. Trials. 2020. PMID: 33308263. doi:10.1186/s13063-020-04910-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。